Hormone replacement therapy (HRT) was overall associated with an increased risk of venous thromboembolism (VTE) compared with not taking it in a study published online Jan. 9, 2019 in BMJ. The risk was 58% higher with oral preparations. Transdermal HRT was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed. Overall, preparations with conjugated equine oestrogen were associated with higher risks than preparations using estradiol. Conjugated equine oestrogen with medroxyprogesterone acetate had the highest risk and estradiol with dydrogesterone had the lowest risk.